Antibody IP transfer agreement

AI SummaryClose X

Fusion Antibodies plc has entered into an Intellectual Property Transfer Agreement with Finn Therapeutics Ltd, a client, for a novel rabbit antibody, receiving a one-off payment of £250,000. This payment, which will be recognized in the current financial year ending March 31, 2026, is for the IP and related reach through to humanized sequences. The agreement includes tailored payment terms to support the client's fundraising activities, and Finn Therapeutics intends to continue its projects with Fusion as the humanized antibody development progresses.

Disclaimer*

UK 100

Latest directors dealings